Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Relmada expects to initiate its Phase 3 program in the first half of 2026
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Subscribe To Our Newsletter & Stay Updated
